65 results on '"NAGATA, Hirohiko"'
Search Results
2. MP53-19 ANDROGEN DEPRIVATION THERAPY THROUGH THE PERI-RADIATION PERIOD REDUCES THE RISK OF BLADDER HEMORRHAGE IN PROSTATE CANCER PATIENTS UNDERGOING EXTERNAL BEAM RADIOTHERAPY
3. Docetaxel‐based chemotherapy combined with dexamethasone 1 mg daily oral administration for castration‐resistant prostate cancer: Long‐term outcomes
4. Prognostic Value of Pretreatment Albumin-to-Globulin Ratio in Patients With Non–Muscle-Invasive Bladder Cancer
5. A clinical study to evaluate the efficacy and safety of docetaxel with ribavirin in patients with progressive castration resistant prostate cancer who have previously received docetaxel alone.
6. Characterizing intermediate-risk non–muscle-invasive bladder cancer: Implications for the definition of intermediate risk and treatment strategy
7. PD48-10 PREOPERATIVE NEUTROPHIL-TO-LYMPHOCYTE RATIO AND SMOKING HISTORY ARE INDEPENDENTLY ASSOCIATED WITH BCG RELAPSING TUMOR RECURRENCE IN NON-MUSCLE INVASIVE BLADDER CANCER PATIENTS
8. MP34-16 COULD ADJUVANT CHEMOTHERAPY HAVE THERAPEUTIC BENEFIT AFTER NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH EQUAL TO OR GREATER THAN PT3 MUSCLE INVASIVE BLADDER CANCER?
9. MP41-11 A PILOT CLINICAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DOCETAXEL WITH RIBAVIRIN IN PATIENTS WITH PROGRESSIVE CASTRATION-RESISTANT PROSTATE CANCER TARGETING STEM-CELL RELATED GENE NETWORK.
10. The efficacy and safety of docetaxel-based chemotherapy combined with dexamethasone 1 mg daily oral administration: JMTO Pca 10-01 phase II trial
11. Female Functional Constipation Is Associated with Overactive Bladder Symptoms and Urinary Incontinence
12. Obstructive sleep apnea syndrome should be considered as a cause of nocturia in younger patients without other voiding symptoms
13. PD11-06 THE ROLE OF SINGLE INSTILLATION CHEMOTHERAPY IN PATIENTS WHO RECEIVE SUBSEQUENT BACILLUS CALMETTE-GUERIN FOR NON-MUSCLE INVASIVE BLADDER CANCER
14. MP13-17 CHARACTERIZING INTERMEDIATE-RISK NON-MUSCLE INVASIVE BLADDER CANCER: IMPLICATIONS FOR THE DEFINITION OF INTERMEDIATE RISK AND TREATMENT STRATEGY
15. Evaluation of histopathological findings at the injection site following degarelix administration
16. Predictive factors for severe and febrile neutropenia during docetaxel chemotherapy for castration-resistant prostate cancer
17. Third-line Hormonal Therapy to Treat Prostate Cancer Relapse after Initial and Second-line Hormonal Therapy: Report of 52 Cases and Literature Review
18. PD23-11 PROSPECTIVE EVALUATION OF EFFICACY AND SAFETY OF SOLIFENACIN AND MIRABEGRON TREATMENT IN BPH PATIENTS TREATED WITH DUTASTERIDE BUT HAVING OAB SYMPTOMS
19. MP32-11 ERECTILE FUNCTION IS HIGHLY ASSOCIATED WITH PROSTATE-SPECIFIC ANTIGEN BOUNCE IN LOCALIZED PROSTATE CANCER PATIENTS TREATED WITH PERMANENT PROSTATE BRACHYTHERAPY
20. MP16-18 DEVELOPMENT OF AN ALGORITHM FOR PREDICTING SEVERE ACUTE EPIDIDYMITIS
21. Prognostic value of preoperative multiparametric magnetic resonance imaging (MRI) for predicting biochemical recurrence after radical prostatectomy
22. 240 PREDICTING PROSTATE SPECIFIC ANTIGEN RECURRENCE AFTER RADICAL PROSTATECTOMY BY CLINICOPATHOLOGICAL FACTORS: SUITABILITY OF MAGNETIC RESONANCE IMAGING
23. 649 COLOR DOPPLER SONOGRAPHIC EVALUATION OF URETERIC JET ANGLE IN DETECTING HIGH GRADE VESICOURETERAL REFLUX IN INFANTS AND YOUNG CHILDREN
24. 2197 BONE SCAN IN PATIENTS WITH NEWLY DIAGNOSED PROSTATE CANCER; TO PERFORM OR NOT?: EXTERNAL VALIDATION OF THE CURRENTLY AVAILABLE GUIDELINES FOR JAPANESE PATIENTS
25. 1165 NOVEL ALGORITHM FOR PREDICTING SEVERE CASES OF ACUTE BACTERIAL PROSTATITIS
26. A Prospective Longitudinal Survey of Erectile Dysfunction in Patients with Localized Prostate Cancer Treated with Permanent Prostate Brachytherapy
27. Human castration resistant prostate cancer rather prefer to decreased 5α-reductase activity
28. Burden of overactive bladder symptom on quality of life in stroke patients
29. Prostate brachytherapy seed migration to a left varicocele
30. Long-term outcomes of children with Xp11.2 translocation renal cell carcinoma.
31. The Efficacy Of Nasal CPAP On Nocturia In Patients With Obstructive Sleep Apnea
32. 963 HOW DOES 5α-REDUCTASE ACTIVITY CHANGE DURING THE PROGRESSION OF CASTRATION RESISTANT PROSTATE CANCER?
33. 1142 A PROSPECTIVE STUDY OF THE EFFECT OF 5-ALPHA-REDUCTASE INHIBITOR (DUTASTERIDE) TREATMENT ON SERUM FREE TESTOSTERONE LEVEL AND AGING MALE SYMPTOMS IN JAPANESE PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA
34. 307 BISEBROMOAMIDE, AS A NOVEL MOLECULAR TARGET DRUG INHIBITING PHOSPHORYLATION OF BOTH EXTRACELLULAR SIGNAL-REGULATED KINASE AND AKT IN RENAL CELL CARCINOMA
35. 1124 PREDICTION AND CLINICAL IMPLICATION OF SEED MIGRATION AFTER BRACHYTHERAPY WITH I-125 FREE SEEDS IN PATIENTS WITH LOCALIZED PROSTATE CANCER
36. 1150 A PROSPECTIVE LONGITUDINAL SURVEY OF ERECTILE DYSFUNCTION RATE IN PATIENTS WITH LOCALIZED PROSTATE CANCER TREATED WITH PERMANENT PROSTATE BRACHYTHERAPY
37. 609 COLOR DOPPLER SONOGRAPHIC EVALUATION OF URETERIC JET ANGLE IN DETECTING HIGH GRADE VESICOURETERAL REFLUX IN CHILDREN
38. Preimplant Factors Affecting Prostate D90 after Transperineal Interstitial Prostate Brachytherapy with Loose 125I Seeds
39. Incidence of seed migration to the chest, abdomen, and pelvis after transperineal interstitial prostate brachytherapy with loose 125I seeds
40. 901 PREDICTION AND STRATIFICATION OF THE DEVELOPMENT OF URINARY RETENTION IN PATIENTS WITH LOCALLY ADVANCED PROSTATE CANCER TREATED WITH HORMONE THERAPY
41. 1265 PROGNOSTIC SIGNIFICANCE OF HIGH NUCLEAR GRADE FOR PATIENTS WITH PATHOLOGIC T1A RENAL CELL CARCINOMA
42. PROSPECTIVE SURVEY OF ERECTILE DYSFUNCTION AFTER EXTERNAL BEAM RADIOTHERAPY FOR PROSTATE CANCER
43. Preimplant factors affecting postimplant CT-determined prostate volume and the CT/TRUS volume ratio after transperineal interstitial prostate brachytherapy with 125I free seeds
44. 1912 CHANGES IN SERUM PROSTATE SPECIFIC ANTIGEN FOLLOWING HOLMIUM LASER ENUCLEATION OF THE PROSTATE IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA
45. 461 PREDICTION AND STRATIFICATION OF ALPHA-BLOCKER DEPENDENCY FOLLOWING BRACHYTHERAPY IN PATIENTS WITH LOCALIZED PROSTATE CANCER
46. 218 DOWN-REGULATION OF MITOGEN-ACTIVATED PROTEIN KINASE PHOSPHATASE-1 EXPRESSION PREDICTS FOR POOR SURVIVAL IN RENAL CELL CARCINOMA
47. Prediction of PSA bounce after permanent prostate brachytherapy for localized prostate cancer
48. ELEVATED EXPRESSION OF ARYL HYDROCARBON RECEPTOR IN RENAL CELL CARCINOMA IS ASSOCIATED WITH CIGARETTE SMOKE AND THE PROGNOSIS
49. ROLE OF ESTROGENS IN PATIENTS WITH HORMONE REFRACTORY PROSTATE CANCER
50. OPTIMIZED URINARY PH IS NECESSARY FOR THE IMPROVEMENT OF ADJUVANT MMC INSTILLATION TREATMENT FOR TUMOR RECURRENCE OF NON-MUSCLE INVASIVE BLADDER TUMORS
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.